Literature DB >> 8549315

Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci.

G A Pankuch1, M R Jacobs, P C Appelbaum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8549315     DOI： 10.2165/00003495-199500492-00053

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  12 in total

1.  Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis.

Authors:  R Munoz; J M Musser; M Crain; D E Briles; A Marton; A J Parkinson; U Sorensen; A Tomasz
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin.

Authors:  J J Gordon; C A Kauffman
Journal:  Am J Med       Date:  1990-09       Impact factor: 4.965

3.  Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia.

Authors:  B Cooper; M Lawlor
Journal:  Am J Med       Date:  1989-10       Impact factor: 4.965

4.  Inappropriate use of oral ciprofloxacin.

Authors:  T R Frieden; R J Mangi
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

Review 5.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

6.  Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis.

Authors:  D J Tweardy; M R Jacobs; W T Speck
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

7.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

8.  In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.

Authors:  T Imada; S Miyazaki; M Nishida; K Yamaguchi; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

9.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

10.  Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States.

Authors:  L K McDougal; R Facklam; M Reeves; S Hunter; J M Swenson; B C Hill; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191
View more
  2 in total

Review 1.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 2.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.